Xilio stockholders elect Class I directors, approve 3x share increase and officer exculpation

Xilio Therapeutics, Inc.

René Russo (32.5M), Sara Bonstein (32.4M), James Shannon (31.0M) elected Class I directors.
Share increase amendment approved: 38.8M for (95.1%), increasing authorized common from 200M to 600M shares; filed June 10.
Officer exculpation amendment approved: 32.3M for (99.3%); filed June 10.
Ernst & Young ratified as auditor for FY2025: 40.7M for (99.7%).

item 5.07

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.